Report cover image

Diabetic Nephropathy Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Oct 01, 2024
Length 120 Pages
SKU # FOB19224239

Description

Diabetic Nephropathy Market



Growth Factors of Diabetic Nephropathy Market

The global diabetic nephropathy market size was valued at USD 2.70 billion in 2023 and is projected to grow from USD 2.81 billion in 2024 to USD 3.99 billion by 2032, exhibiting a CAGR of 4.5% during the forecast period of 2024-2032.

This chronic illness disrupts the behind-schedule prognosis and treatment in the Diabetic Nephropathy Market because of limitations on healthcare admission and delayed trials. But, as other acts related to healthcare provision standardize, increased cases of diabetes and better awareness of kidney pains will, in turn, boost market expansion, thus restraining the diabetic nephropathy market growth.

The growth drivers for the Diabetic Nephropathy Market are the increasing prevalence of diabetes, increasing awareness of diabetic complications, and technological progress in the treatments. Growth in the prices of health and the advancement of fresh healing procedures contribute to the marketplace enlargement.

Remote monitoring and telemedicine are gradually becoming more and more crucial for controlling diabetic nephropathy. CGM gadgets show precise actual-time Blood Glucose degree knowledge to the sufferers and healthcare suppliers to make the suitable choice on insulin dosing and everyday way-of-life adjustments that would contribute to expanding the worldwide diabetic nephropathy market share. Telehealth platform Cornerstone also enables distant monitoring of patients with diabetic nephropathy and identifies potential complications and timely intervention. It can grow patient outcomes, reduce pressure on health systems, and improve regular, high-quality care.

Comprehensive Analysis of Diabetic Nephropathy Market

The Diabetic Nephropathy Market is segmented via drug magnificence and distribution channels. In terms of drug class, angiotensin receptor blockers maintain the most significant marketplace proportion due to their capacity to save nephropathy in diabetic sufferers. ACE inhibitors are also widely used, with medical research showing they sluggish the progression of kidney disorders. The SGLT2 inhibitors section is projected to develop quickly due to its blessings in decreasing renal fibrosis and related complications. Regarding distribution channels, clinic pharmacies dominate the market, driven by high hospitalization rates for persistent kidney sickness, even as drug shops and retail pharmacies preserve a significant percentage because they provide prescription and OTC drugs.

The North America region led the diabetic nephropathy market by benefitting a size of USD 1.19 billion in 2023 due to the rising prevalence of diabetes.

The leading players in the diabetic nephropathy market significantly shape its growth trajectory and establish industry standards. These key companies, including Janssen Pharmaceuticals, Inc. (U.S.), AstraZeneca (U.K.), Aurobindo Pharma Limited (India), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), and Par Pharmaceuticals (U.S.), contribute to a competitive landscape, driving innovation and advancing the market.

In November 2023, ProKidney Corp. Secured approval from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and obtained medical steerage from the European Medicines Agency (EMA) concerning phase 3 protocols for REACT in diabetic chronic kidney disease.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 4.5% from 2024-2032

Unit Value (USD Billion)

Segmentation By Drug Class
  • Angiotensin Converting Enzyme (ACE) Inhibitors
  • Angiotensin Receptor Blockers
  • Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Others
By Geography
  • North America (By Drug Class, By Distribution Channel, and By Country)
  • U.S.
  • Canada
  • Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
  • Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
  • Rest of the World (By Drug Class, and By Distribution Channel)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

120 Pages
1. Introduction
1.1. Market Scope
1.2. Market Segmentation
1.3. Market Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Key Industry Developments – Merges, Acquisitions, and Partnerships
4.2. New Product Launches, By Key Players
4.3. Prevalence of Diabetic Nephropathy, By Key Countries
4.4. Pipeline Analysis (Analysis by Stage, Route of Administration, Molecule Type, Sponsor, etc.)
4.5. Insights on Usage of SGLT2 Inhibitors in CKD Stage 3 Patients
4.6. Drugs Delaying Dialysis Onset: Analysis of Ongoing Studies
4.7. List of Research & Educational Institutes in R&D
4.8. Impact of COVID 19 on the Global Diabetic Nephropathy Market
5. Global Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Drug Class
5.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
5.1.2. Angiotensin Receptor Blockers
5.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
5.1.4. Mineralocorticoid Receptor Antagonists
5.1.5. Others
5.2. Market Analysis, Insights and Forecast – By Distribution Channel
5.2.1. Hospital Pharmacies
5.2.2. Drug Stores & Retail Pharmacies
5.2.3. Others
5.3. Market Analysis, Insights and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Rest of the World
6. North America Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Drug Class
6.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
6.1.2. Angiotensin Receptor Blockers
6.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.1.4. Mineralocorticoid Receptor Antagonists
6.1.5. Others
6.2. Market Analysis, Insights and Forecast – By Distribution Channel
6.2.1. Hospital Pharmacies
6.2.2. Drug Stores & Retail Pharmacies
6.2.3. Others
6.3. Market Analysis, Insights and Forecast – By Country
6.3.1. U.S.
6.3.2. Canada
7. Europe Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Drug Class
7.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
7.1.2. Angiotensin Receptor Blockers
7.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
7.1.4. Mineralocorticoid Receptor Antagonists
7.1.5. Others
7.2. Market Analysis, Insights and Forecast – By Distribution Channel
7.2.1. Hospital Pharmacies
7.2.2. Drug Stores & Retail Pharmacies
7.2.3. Others
7.3. Market Analysis, Insights and Forecast – By Country/Sub-region
7.3.1. U.K.
7.3.2. Germany
7.3.3. France
8. 7.3.4.I taly
8.1.
8.1.1. Spain
8.1.2. Scandinavia
8.1.3. Rest of Europe
9. Asia Pacific Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Drug Class
9.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
9.1.2. Angiotensin Receptor Blockers
9.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
9.1.4. Mineralocorticoid Receptor Antagonists
9.1.5. Others
9.2. Market Analysis, Insights and Forecast – By Distribution Channel
9.2.1. Hospital Pharmacies
9.2.2. Drug Stores & Retail Pharmacies
9.2.3. Others
9.3. Market Analysis, Insights and Forecast – By Country/Sub-region
9.3.1. Japan
9.3.2. China
9.3.3. India
9.3.4. Australia
9.3.5. Southeast Asia
9.3.6. Rest of Asia Pacific
10. Rest of the World Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Drug Class
10.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors
10.1.2. Angiotensin Receptor Blockers
10.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
10.1.4. Mineralocorticoid Receptor Antagonists
10.1.5. Others
10.2. Market Analysis, Insights and Forecast – By Distribution Channel
10.2.1. Hospital Pharmacies
10.2.2. Drug Stores & Retail Pharmacies
10.2.3. Others
11. Comparative Analysis
11.1. Global Market Share Analysis (2023)
11.2. Company Profiles
11.2.1. Janssen Pharmaceuticals, Inc.
11.2.1.1. Overview
11.2.1.2. Products & Services
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. AstraZeneca
11.2.2.1. Overview
11.2.2.2. Products & Services
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Aurobindo Pharmaceuticals
11.2.3.1. Overview
11.2.3.2. Products & Services
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. Novartis AG
11.2.4.1. Overview
11.2.4.2. Products & Services
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. Sanofi
11.2.5.1. Overview
11.2.5.2. Products & Services
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Bayer AG
11.2.6.1. Overview
11.2.6.2. Products & Services
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. Par Pharmaceutical
11.2.7.1. Overview
11.2.7.2. Products & Services
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. Sun Pharmaceutical Industries
11.2.8.1. Overview
11.2.8.2. Products & Services
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Teva Pharmaceutical Industries Ltd.
11.2.9.1. Overview
11.2.9.2. Products & Services
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
12.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us